Home / Artifacts / Hippocampal CA3 Pyramidal Neurons in Alzheimer's Diseas

📖

Hippocampal CA3 Pyramidal Neurons in Alzheimer's Disease

active

wiki page Created: 2026-04-02T20:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-cell-types-hippocampal-ca3-pyramida

Related Entities

cell-types-hippocampal-ca3-pyramidal-alzheimers

Metadata

slug	cell-types-hippocampal-ca3-pyramidal-alzheimers
kg_node_id	None
entity_type	cell

📊 Evidence Profile

Evidence Balance

+0%

Certainty

100%

Debates

Incoming

217

Outgoing

232

0 supporting 0 contradicting 0 neutral

View full evidence profile →

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

This artifact has no version history yet.

Linked Artifacts (331)

see_also📖Novartis Alzheimer's Disease Phase 2 Trial (NCT0709451680%

see_also📖NCT07477431 - Levetiracetam for Persons at Risk for Alzheime80%

see_also📖Ozanimod for Alzheimer's Disease (NCT06862960)80%

see_also📖Sporadic Alzheimer's Disease Pathway80%

see_also📖TRAILBLAZER-ALZ 3 (NCT05026866) — Donanemab for Preclinical 80%

see_also📖NLRP3 Inflammasome Pathway in Alzheimer's Disease80%

see_also📖KarXT for Alzheimer's Disease Cognitive Impairment - MI80%

see_also📖MK-2214 for Early Alzheimer's Disease80%

see_also📖BMS-986446 Phase 2 Trial for Early Alzheimer's Disease80%

see_also📖Masupirdine for Agitation in Alzheimer's Disease (NCT0580%

see_also📖LEAF Trial - THC+CBD for Alzheimer's Disease Agitation 80%

see_also📖Cannabidiol for Alzheimer's Disease Prevention (NCT058280%

see_also📖Metal Ion Homeostasis in Alzheimer's Disease80%

see_also📖Digital Biomarkers for Alzheimer's Disease80%

see_also📖KarXT (Xanomeline/Trospium) - Phase 3 for Alzheimer's D80%

see_also📖Cholinergic System Degeneration in Alzheimer's Disease80%

see_also📖Sleep and Circadian Dysfunction in Alzheimer's Disease80%

see_also📖MAR Polypill for Alzheimer's Disease (NCT06597058)80%

see_also📖X/T + X-EC + Lecanemab Phase 2 (NCT07212062) — Alzheimer80%

see_also📖Diffuse Amyloid Deposits in Alzheimer's Disease80%

see_also📖NRTIs for Alzheimer's Disease: Targeting Type-I Interfe80%

related🧪Prefrontal sensory gating circuit restoration via PV interne80%

related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation80%

see_also📖GSK4527226 (AL101) for Early Alzheimer's Disease (NCT0680%

see_also📖Recombinant Human Serum Albumin for Alzheimer's Disease80%

see_also📖Glymphatic System in Alzheimer's Disease80%

see_also📖NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease80%

see_also📖Endolysosomal Pathway in Alzheimer's Disease80%

see_also📖CD33 Siglec Receptor Dysfunction Alzheimer's Disease Ca80%

see_also📖GFAP in Alzheimer's Disease80%

see_also📖DTI Biomarkers for Alzheimer's Disease80%

related🧪Extracellular Vesicle Biogenesis Modulation80%

see_also📖ACP-204 for Alzheimer's Disease Psychosis (NCT06159673)80%

see_also📖Gait Biomarkers for Alzheimer's Disease80%

see_also📖Ubiquitin-Proteasome System Dysfunction in Alzheimer's 80%

see_also📖LHP588: P. gingivalis Targeting for Alzheimer's Disease80%

see_also📖EI-1071 Immunomodulator for Alzheimer's Disease (NCT06780%

see_also📖Neuroinflammation Hypothesis in Alzheimer's Disease80%

see_also📖Speech and Cognitive Biomarkers for Alzheimer's Disease80%

see_also📖Tau Kinase Signaling Cascade in Alzheimer's Disease80%

see_also📖TRAILRUNNER-ALZ 1: Remternetug for Early Alzheimer's Di80%

see_also📖Adipose-Derived Mesenchymal Stem Cell Therapy for Early Alzh80%

see_also📖Mitochondrial Dysfunction in Alzheimer's Disease Pathwa80%

related🧪Trans-Synaptic Adhesion Molecule Modulation80%

related🧪LRP1-Dependent Tau Uptake Disruption80%

see_also📖VY7523 Phase 1/2 Alzheimer's Disease Trial80%

see_also📖BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer80%

see_also📖ONO-2020 for Alzheimer's Disease (NCT06881836)80%

related🧪Gamma entrainment therapy to restore hippocampal-cortical sy80%

see_also📖Synaptic Loss in Alzheimer's Disease Pathway80%

see_also📖Piromelatine 20 mg for Mild Dementia Due to Alzheimer's80%

see_also📖The Alzheimer's Disease Tau Platform Clinical Trial (NC80%

see_also📖KarXT for Alzheimer's Disease Cognitive Impairment - MI80%

see_also📖Alzheimer's Disease Biomarkers80%

related🧪APOE Isoform Expression Across Glial Subtypes80%

see_also📖EX039 Phase 2 (NCT05413655) — Oral Therapeutic for Alzheimer80%

related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK80%

related🧪TREM2-mediated microglial tau clearance enhancement80%

see_also📖ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT05680%

related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia80%

see_also📖Inflammatory Biomarkers in Alzheimer's Disease80%

see_also📖[F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disea80%

see_also📖Geniposide for Alzheimer's disease - immune biomarker t80%

see_also📖Exciva Alzheimer's Disease Phase 2/3 Trial80%

see_also📖Locus Coeruleus Degeneration in Alzheimer's Disease80%

see_also📖IGC-AD1 for Agitation in Alzheimer's Disease (NCT05543680%

see_also📖Neuroinflammation in Alzheimer's Disease80%

related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro80%

see_also📖Foralumab Phase 2 Trial for Alzheimer's Disease80%

see_also📖Escitalopram for Agitation in Alzheimer's Disease (NCT080%

related🧪HSP90-Tau Disaggregation Complex Enhancement80%

see_also📖Probiotics in Mild Alzheimer's Disease (NCT06181513)80%

see_also📖Siponimod for Alzheimer's Disease (NCT06639282)80%

see_also📖Sex-Specific Mechanisms in Alzheimer's Disease80%

related🧪Synaptic Vesicle Tau Capture Inhibition80%

see_also📖PLX5622 CSF1R Inhibitor Trial in Early Alzheimer's Dise80%

see_also📖Plasma Phospho-Tau Ratio Diagnostic Panel for Alzheimer'80%

see_also📖Dried Blood Spot Biomarker Test for Alzheimer's Disease80%

see_also📖TRAP-AD: Transcranial Photobiomodulation for Alzheimer'80%

see_also📖APOE Lipid Metabolism Pathway in Alzheimer's Disease80%

see_also📖GSK4527226 (AL101) for Early Alzheimer's Disease (NCT0680%

see_also📖SHR-1707 for Alzheimer's Disease (NCT06199037)80%

see_also📖VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers80%

related🧪Complement C1QA Spatial Gradient in Cortical Layers80%

see_also📖NRTIs for Alzheimer's Disease - Phase 1 (NCT07210528)80%

see_also📖Neurovascular Dysfunction in Alzheimer's Disease: Integ80%

see_also📖Vascular Dementia Mechanisms — Overlap with Alzheimer's80%

see_also📖NAB-IT: Nabilone for Agitation in Alzheimer's Disease80%

see_also📖Biogen Alzheimer's Disease Phase 2 Trial (NCT05399888)80%

see_also📖Alzheimer's Disease Mechanism Index80%

see_also📖Master Screening Study to Determine Individuals With Potenti80%

see_also📖Masupirdine for Alzheimer's Disease Agitation80%

see_also📖Synaptic Therapy Alzheimer's Research Trial (START): A 80%

see_also📖Olfactory Biomarkers for Alzheimer's Disease80%

see_also📖Neurogranin - Alzheimer's Disease Biomarker80%

see_also📖Synaptic Biomarkers for Alzheimer's Disease80%

see_also📖SNIFF-Combo: Intranasal Insulin + Empagliflozin for Alzheime80%

see_also📖Rotigotine and Rivastigmine Combination Therapy for Alzheime80%

see_also📖Nabilone for Agitation in Alzheimer's Disease (NCT0451680%

see_also📖Ocular Fluid Biomarkers for Alzheimer's Disease80%

see_also📖NCT03875638 - Levetiracetam for Alzheimer's Disease80%

see_also📖DMB-I (Latrepirdine) Phase 3 (NCT07251023) — Alzheimer'80%

see_also📖Sleep Biomarkers for Alzheimer's Disease80%

related🧪VCP-Mediated Autophagy Enhancement80%

see_also📖Eye-Tracking Digital Markers in Alzheimer's Disease80%

see_also📖NCT06803823 - ONO-2020 for Agitation in Alzheimer's Dis80%

see_also📖EEG Biomarkers for Alzheimer's Disease80%

see_also📖APOE4 and Alzheimer's Disease Risk80%

see_also📖BMS-986368 Phase 2 - Agitation in Alzheimer's Disease80%

see_also📖Centella asiatica Phase 1 Trial for Alzheimer's Disease80%

see_also📖NCT07262645: Near-Infrared Light Therapy for Mild-Moderate A80%

see_also📖Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Dise80%

related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli80%

see_also📖EEG Microstates in Alzheimer's Disease80%

see_also📖CBD (Cannabidiol) for Alzheimer's Disease Agitation - N80%

see_also📖Salivary Biomarkers for Alzheimer's Disease80%

see_also📖NCT06582706: Nicotinic Acid for Alzheimer's Disease80%

see_also📖ExPlas — Exercise Plasma Transfusion for Alzheimer's Di80%

related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation80%

see_also📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St80%

see_also📖Tau Kinase-Phosphatase Balance in Alzheimer's Disease80%

see_also📖Tear Film Biomarkers in Alzheimer's Disease80%

see_also📖SToP-AD: Suvorexant for Alzheimer's Disease Prevention80%

see_also📖Fasudil for Early Alzheimer's Disease (FEAD) - NCT0636280%

see_also📖GV1001 for Moderate to Severe Alzheimer's Disease (NCT080%

see_also📖ITI-1284 for Alzheimer's Disease Psychosis (NCT0654083380%

see_also📖Senicapoc Alzheimer's Disease Trial - NCT0480424180%

see_also📖Guanfacine NorAD - Phase 3 Trial for Alzheimer's Diseas80%

see_also📖ASL Perfusion Biomarkers for Alzheimer's Disease80%

related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK72%

related🧪Complement C1QA Spatial Gradient in Cortical Layers72%

related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation72%

related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation72%

related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia72%

related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli72%

related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro72%

related🧪APOE Isoform Expression Across Glial Subtypes72%

related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%

related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%

related🧫Protein Aggregation Kinetic Validation Results70%

related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%

related🧫Protein Aggregation Kinetic Validation Results70%

related🧫Experiment Validation: In vitro ThT Assay70%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%

related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%

related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%

related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%

related🧫Experiment Validation: In vitro ThT Assay70%

related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%

related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%

related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%

related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%

related🧫Proposed experiment from debate on Synaptic pruning by micro60%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD60%

related🧫4R-Tau Targeting Therapies for PSP and CBS60%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%

related🧫tACS Connectivity Trial in Early Alzheimer's60%

related🧫Vascular Contribution to Alzheimer's Disease — Beyond A60%

related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#60%

related🧫s:** - Test whether HCN1 knockout specifically in EC layer I60%

related🧫Sex Differences in Alzheimer's Disease — mechanisms and60%

related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease60%

related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa60%

related🧫Sleep Disruption and Alzheimer's Disease — mechanism an60%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%

related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera60%

related🧫Blood-Based Biomarker Panel for Early AD Detection60%

related🧫Microglial TREM2 Agonist In Vivo Efficacy60%

related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera60%

related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech60%

related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis60%

related🧫Neural Stem Cell Therapy for Alzheimer's Disease60%

related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti60%

related🧫Tau ASO Therapy60%

related🧫Traumatic Brain Injury and Alzheimer's Disease Relation60%

related🧫Autophagy Enhancement Drug Screening for Neurodegeneration60%

related🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas60%

related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M60%

related🧫Mixed Pathology Effects on Parkinson's Disease Progress60%

related🧫Viral Infections and Alzheimer's Disease — causal mecha60%

related🧫Anti-Tau Immunotherapy Dosing Optimization60%

related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise60%

related🧫Experiment: Autoimmune Hypothesis Testing in AD60%

related🧫ApoE4 Function in Alzheimer's Disease60%

related🧫Gap Junction Dysfunction Validation in Parkinson's Dise60%

related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi60%

related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation60%

related🧫Normal Aging to Alzheimer's Disease Transition Trigger 60%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD60%

related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol60%

related🧫Prion Strain Diversity and Selective Vulnerability60%

related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr60%

related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?60%

related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 60%

related🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau60%

related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#60%

related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia60%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%

related🧫ApoE4 Function in Alzheimer's Disease54%

related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi54%

related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?54%

related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr54%

related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease54%

related🧫Gap Junction Dysfunction Validation in Parkinson's Dise54%

related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis54%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%

related🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau54%

related🧫s:** - Test whether HCN1 knockout specifically in EC layer I54%

related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol54%

related🧫Vascular Contribution to Alzheimer's Disease — Beyond A54%

related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#54%

related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera54%

related🧫Anti-Tau Immunotherapy Dosing Optimization54%

related🧫Proposed experiment from debate on Synaptic pruning by micro54%

related🧫Autophagy Enhancement Drug Screening for Neurodegeneration54%

related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera54%

related🧫4R-Tau Targeting Therapies for PSP and CBS54%

related🧫Sleep Disruption and Alzheimer's Disease — mechanism an54%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%

related🧫Sex Differences in Alzheimer's Disease — mechanisms and54%

related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 54%

related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti54%

related🧫Blood-Based Biomarker Panel for Early AD Detection54%

related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa54%

related🧫tACS Connectivity Trial in Early Alzheimer's54%

related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech54%

related🧫Mixed Pathology Effects on Parkinson's Disease Progress54%

related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise54%

related🧫Tau ASO Therapy54%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%

related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia54%

related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation54%

related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M54%

related🧫Traumatic Brain Injury and Alzheimer's Disease Relation54%

related🧫Microglial TREM2 Agonist In Vivo Efficacy54%

related🧫Normal Aging to Alzheimer's Disease Transition Trigger 54%

related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#54%

related🧫Prion Strain Diversity and Selective Vulnerability54%

related🧫Experiment: Autoimmune Hypothesis Testing in AD54%

related🧫Neural Stem Cell Therapy for Alzheimer's Disease54%

related🧫Viral Infections and Alzheimer's Disease — causal mecha54%

related🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas54%

related🔬Can gut-brain axis modulation prevent or slow Alzheimer'50%

related🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph50%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

related🔬What are the mechanisms underlying selective vulnerability o50%

related🔬Investigate prion-like spreading of tau pathology through co50%

related🔬What cell types are most vulnerable in Alzheimer's Dise50%

related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%

mentions🧪Synthetic Biology BBB Endothelial Cell Reprogramming50%

related🔬Investigate prion-like spreading of tau pathology through co50%

mentions🧪Gamma entrainment therapy to restore hippocampal-cortical sy50%

mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna50%

related🔬What are the mechanisms underlying mitochondrial transfer be50%

mentions🧪Trans-Synaptic Adhesion Molecule Modulation50%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

related🔬Comprehensive analysis of immune cell subtypes in neurodegen50%

related🔬Mitochondrial transfer between astrocytes and neurons50%

related🔬What are the mechanisms underlying senolytic therapy for age50%

mentions🧪Synaptic Vesicle Tau Capture Inhibition50%

related🔬What are the mechanisms underlying selective vulnerability o50%

mentions🧪TREM2-mediated microglial tau clearance enhancement50%

related🔬Why do entorhinal cortex layer II stellate neurons die first50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

related🔬What are the mechanisms underlying blood-brain barrier trans50%

mentions🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%

mentions🧪Senescent Cell Mitochondrial DNA Release50%

related🔬What cell types are most vulnerable in Alzheimers Disease ba50%

mentions🧪VCP-Mediated Autophagy Enhancement50%

related🔬What are the mechanisms underlying mitochondrial transfer be50%

related🔬What are the mechanisms underlying what are the mechanisms b50%

related🔬What are the mechanisms underlying senolytic therapy for age50%

related🔬How to break the GBA-alpha-synuclein bidirectional loop for 50%

mentions🧪Extracellular Vesicle Biogenesis Modulation50%

mentions🧪LRP1-Dependent Tau Uptake Disruption50%

related🔬What are the most promising therapeutic strategies for targe50%

mentions🧪HSP90-Tau Disaggregation Complex Enhancement50%

related🔬The disease-associated microglia (DAM) phenotype involves TR50%

mentions🧪Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener50%

mentions🧪Prefrontal sensory gating circuit restoration via PV interne50%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

mentions🧪Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem50%

related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%

related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna50%

related🧪Trans-Synaptic Adhesion Molecule Modulation40%

related🧪Synthetic Biology BBB Endothelial Cell Reprogramming40%

related🧪VCP-Mediated Autophagy Enhancement40%

related🧪Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener40%

related🧪Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem40%

mentions🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc40%

related🧪Synaptic Vesicle Tau Capture Inhibition40%

mentions🔬Can gut-brain axis modulation prevent or slow Alzheimer'40%

related🧪LRP1-Dependent Tau Uptake Disruption40%

related🧪Senescent Cell Mitochondrial DNA Release40%

mentions🔬Why do entorhinal cortex layer II stellate neurons die first40%

mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen40%

mentions🔬How to break the GBA-alpha-synuclein bidirectional loop for 40%

related🧪TREM2-mediated microglial tau clearance enhancement40%

mentions🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc40%

mentions🔬What are the mechanisms underlying selective vulnerability o40%

mentions🔬Mitochondrial transfer between astrocytes and neurons40%

mentions🔬What cell types are most vulnerable in Alzheimer's Dise40%

mentions🔬Analyze circuit-level changes in neurodegeneration using All40%

mentions🔬What cell types are most vulnerable in Alzheimers Disease ba40%

related🧪Prefrontal sensory gating circuit restoration via PV interne40%

related🧪HSP90-Tau Disaggregation Complex Enhancement40%

mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%

mentions🔬What are the mechanisms underlying mitochondrial transfer be40%

mentions🔬What are the most promising therapeutic strategies for targe40%

related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna40%

mentions🔬What are the mechanisms underlying what are the mechanisms b40%

mentions🔬What are the mechanisms underlying mitochondrial transfer be40%

related🧪Extracellular Vesicle Biogenesis Modulation40%

mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%

mentions🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph40%

related🧪Gamma entrainment therapy to restore hippocampal-cortical sy40%

related🧪Age-Dependent Complement C4b Upregulation Drives Synaptic Vu35%

💬 Discussion

Loading comments...